Fabrication and Evaluation of Hyaluronic Acid Coated Albumin Nanoparticles for Delivery of Gemcitabine.
Shweta Paroha, Ravindra Dhar Dubey, Juhi Verma, Vikas Jain, Saleem Akbar, Ashwini Kumar Mishra, S L Neha, Laxmi Rani, Aman Kumar Mahto, Parvat Kumar Sahoo, Rikeshwer Prasad Dewangan
Author Information
Shweta Paroha: Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University, New Delhi-110017, India.
Ravindra Dhar Dubey: Formulation Division, Invictus Oncology Private Limited, New Delhi-110092, India.
Juhi Verma: Product Development Cell, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi-110067, India.
Vikas Jain: Injectable Pharma Research, Lupin Research Park, Lupin Limited, Pune-412115, India.
Saleem Akbar: Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India. ORCID
Ashwini Kumar Mishra: Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University, New Delhi-110017, India.
S L Neha: Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University, New Delhi-110017, India.
Laxmi Rani: Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University, New Delhi-110017, India.
Aman Kumar Mahto: Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India.
Parvat Kumar Sahoo: Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University, New Delhi-110017, India.
Rikeshwer Prasad Dewangan: Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India.
Gemcitabine (Gem) is a well-known antineoplastic drug used for several solid tumors. The clinical application of gem is hampered owing to non-selectivity, short half-life, and drug resistance, which necessitate the development of a suitable novel formulation that can selectively target cancer sites. In the present work, Gem-loaded bovine serum albumin nanoparticles (Gem-BSANPs) have been prepared and coated with hyaluronic acid (HA-Gem-BSANPs). Particle size, zeta potential, TEM, and DSC analysis characterized the developed NPs. The mean particle size, PDI, and zeta potentials were observed to be 120.9 �� 5.87 vs 144.7 �� 5.67 and 28.66 �� 1.10 vs -45.72 �� 3.24, for Gem-BSANPs and HA-Gem-BSANPs, respectively. Interestingly, HA-coated Gem-BSANPs were found higher cytotoxic against A549 cell lines with better killing kinetics and mitochondrial membrane loss due to overexpression of CD44. The present work demonstrated that HA-Gem-BSANPs could be a potential strategy to improve the therapeutic efficacy of gem by selectively targeting to the tumor site.
